United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Johnson & Johnson

Moderna

"The data are about as good as it gets," Dr. Anthony Fauci told CNBC, saying he expects Pfizer, Moderna and J&J's vaccines to receive full FDA approval.

Fauci says he would be 'astounded' if Pfizer, Moderna and J&J Covid vaccines don't get full FDA approval

Boosters could add billions to revenue in the long term.

Pfizer vs. Moderna: Which Company's Booster Will Dominate?

The global tally for the coronavirus-borne illness climbed above 187 million on Tuesday, while the death toll climbed further above 4.03 million, according to data aggregated by Johns Hopkins University. The U.S. leads the world with a total of 33.88 million cases and in deaths with 607,400.The Food and Drug Administration told Pfizer executives that it sees no need for vaccine boosters right now.

Coronavirus tally: Global cases of COVID-19 187 million as FDA tells Pfizer no boosters needed for now

There's a bit of a brouhaha over booster doses.

Why the CDC and FDA Just Slapped Down Pfizer and Moderna

AstraZeneca

BioNTech SE

Novavax

Based on company forecasts, Wall Street estimates, and author guestimates, the top coronavirus vaccine developers will bring in billions of dollars in sales this year.

COVID-19 Vaccines: How Much Revenue Will Each Drugmaker Generate in 2021?

• Pharmaceutical company seeks FDA approval for third dose

Pfizer pushes for booster shots as WHO says greed is driving vaccine disparities

The meeting comes amid a public dispute between the drugmaker and U.S. officials on if and when Americans will need additional doses of the Covid vaccines.

Pfizer to make case to U.S. officials Monday on need for Covid vaccine booster shots

It has to do with the companies' next step in the coronavirus vaccine rollout.

Does This Shocking CDC Statement Mean Trouble for Pfizer and Moderna?

Pfizer appears likely to break out of its multi-year trading range. Pfizer's exposure to the Covid-19 vaccine appears underappreciated, which is likely to correct in the second half of 2021.

Pfizer Shares Likely To Get A Boost In The Second Half Of 2021

Biogen

Novartis

uniQure

Roche Holding AG

SAGE Therapeutics

Several drugmakers have important clinical trial updates on the way.

Late-Stage Clinical Study Readouts Biotech Investors Should Watch

Dr. Scott Gottlieb says the United States "probably missed the window" to provide the follow-up doses before a summer wave of infections.

Declining Vaccine Efficacy—Particularly Among Older Individuals—Prompting Pfizer's Emergency Booster Request, Former FDA Chief Says

Bayer AG

Regeneron Pharmaceuticals

Now's the time to get into these companies while their valuation is still favorable.

3 Top Biotech Stocks to Buy in July

Pfizer/BioNTech COVID vaccine dominating global supply and dramatically distorting Pfizer's business. Pfizer/BioNTech COVID vaccine use being broadened to pregnant women and very young children.

Pfizer: mRNA Vaccines Not A Flash In The Pan

Pfizer announced on Thursday that it's seeking authorization for a booster shot - a third dose of its existing coronavirus vaccine - next month.

Booster shots aren't necessary right now, US health agencies say. Pfizer is seeking authorization anyway.

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) announced Thursday that they are developing a COVID-19 booster dose intended to target the delta variant. What Happened: The companies expect to shortly seek U.S. authorization for a third dose of its vaccine.

Pfizer, BioNTech Working On COVID-19 Booster Shot Targeting Delta Variant

BioNTech (BNTX) and partner Pfizer plan to get authorization for COVID-19 booster vaccine shot in the United States owing the emerging Delta variant of the virus.

BioNTech (BNTX)/ Pfizer to Seek FDA Nod for COVID-19 Booster

The company is laying out a timeline for vaccine boosters as the Delta variant takes over.

Why Shares of Pfizer Are Rising Today

PFE stock is gaining these morning even as the FDA pushes back against Pfizer booster trial news and plans for a new shot. The post What to Know About the Pfizer Booster Trial and New Vaccine Moves for PFE Stock appeared first on InvestorPlace.

What to Know About the Pfizer Booster Trial and New Vaccine Moves for PFE Stock

Shares of Pfizer Inc. gained 1.9% in trading on Friday, the day after the company put out a statement saying it plans to share clinical data for its experimental COVID-19 booster shot in August. Pfizer previously told investors it would share that data and submit an application for emergency authorization in July.

Pfizer says COVID-19 booster shot data coming in August, not July

Will This Efficacy Stumble Hurt Pfizer?

Pfizer Inc (NYSE:PFE) has asked US regulators for permission to administer a third dose of its Covid-19 vaccine in an attempt to ward new virus mutations such as the Delta variant. The news came as infections continue to surge in the UK with the latest data showing the infection rate is now one in 160 compared to one in 260 last week.

Pfizer asks for Covid-19 booster shot permission as UK infection rate jumps again

Getty ImagesIn an unusual exchange, the Food and Drug Administration and the Center for Disease Control on Thursday said there isn't scientific evidence that COVID-19 booster shots are required, hours after drug maker Pfizer PFE said it would seek authorization for a Covid booster shot to help contain the Delta variant.Pfizer PFE and its German biotech partner BioNtech BNTX had indicated that initial study data encouraged them to seek authorization for a booster shot, with evidence that there is a greater risk of reinfection six months after a vaccination.The two companies said that such a shot after six months produces antibodies 5 to 10 times higher than after two doses, and that it could provide high degrees of protection against the highly transmissible and fast-spreading Delta variant.The FDA and the CDC said in their release that “Americans who have been fully vaccinated do not need a booster shot at this time,” and that they were “prepared for booster doses if and when the science demonstrates that they are needed.”Mary Daly, the president of the Federal Reserve of San Francisco, warned in an interview with the Financial Times on Friday that because of the Delta variant, “to premature declare victory on Covid” was “the biggest risk to global growth going forward.

U.S. drug regulators unmoved by Pfizer plan to seek Covid booster authorization

Delta Air Lines

The global tally for the coronavirus-borne illness rose above 185.5 million on Friday, while the death toll climbed further above 4.01 million, according to data aggregated by Johns Hopkins University. The U.S. leads the world with a total of 33.79 million cases and in deaths with 606,476.

Coronavirus tally: Global cases of COVID-19 top 185.5 million and Pfizer to develop booster against delta variant

Maybe, but it's still too soon to know for sure.

Could Pfizer and Moderna Be in Trouble After the Latest COVID Vaccine Findings?

The companies are also working on an updated shot designed to take the Delta variant of the infection.

News for Pfizer Stock (PFE)